Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 30, 2025 08:40 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first...
September 25, 2025 08:45 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA...
September 11, 2025 09:17 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi)...
September 11, 2025 07:00 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses Results Provide Further...
September 04, 2025 09:25 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL204 Phase 2/3 Clinical Trials Expected to Commence in First Half of 2026...
September 02, 2025 08:45 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...
August 12, 2025 08:00 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

GRAND CAYMAN, Cayman Islands, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA...
August 05, 2025 16:11 ET | Source: Dyadic International, Inc.

Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable...
July 31, 2025 20:00 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference...
July 31, 2025 09:55 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Grand Cayman, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...